These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31078421)

  • 1. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer.
    Li H; Verma V; Brooks ED; Feng L; Zhang T; Welsh JW; Lin SH; Gomez D; Gandhi S; Heymach JV; Chang JY
    Clin Lung Cancer; 2019 Jul; 20(4):e480-e488. PubMed ID: 31078421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
    JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
    Wink KCJ; Löck S; Rossi M; van Baardwijk A; Belderbos J; de Ruysscher D; Troost EGC
    Radiother Oncol; 2019 Feb; 131():120-126. PubMed ID: 30773178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
    Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
    Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.
    Verma V; Hasan S; Wegner RE; Abel S; Colonias A
    Radiother Oncol; 2019 Feb; 131():145-149. PubMed ID: 30773182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
    Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
    Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
    Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I; Sandhu S; Lüchtenborg M; Harden S
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer.
    Mihai A; Milano MT; Santos A; Kennedy A; Thirion P; McDermott RS; Westrup J; Rock L; Armstrong J
    J Geriatr Oncol; 2019 May; 10(3):442-448. PubMed ID: 30420322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
    McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
    BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Chang JY; Lin SH; Dong W; Liao Z; Gandhi SJ; Gay CM; Zhang J; Chun SG; Elamin YY; Fossella FV; Blumenschein G; Cascone T; Le X; Pozadzides JV; Tsao A; Verma V; Welsh JW; Chen AB; Altan M; Mehran RJ; Vaporciyan AA; Swisher SG; Balter PA; Fujimoto J; Wistuba II; Feng L; Lee JJ; Heymach JV
    Lancet; 2023 Sep; 402(10405):871-881. PubMed ID: 37478883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
    Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.